Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ANL is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
18 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 14 days ago
Red flags: 1
42 filers reported a long position in ANL for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Cormorant Asset Management, LP | $45.7M | 4M | +37.3% |
| Venrock Adviser, LLC | $36.9M | 3.2M | Unchanged |
| BALYASNY ASSET MANAGEMENT L.P. | $35.2M | 3.1M | +248.8% |
| Point72 Asset Management, L.P. | $24.6M | 2.1M | New |
| MPM BioImpact LLC | $22.3M | 1.9M | New |
| PERCEPTIVE ADVISORS LLC | $20.6M | 1.8M | New |
| Casdin Capital, LLC | $14.4M | 1.3M | +132.1% |
| ADAR1 Capital Management, LLC | $11.7M | 1M | +763.2% |
| Octagon Capital Advisors LP | $10.7M | 934.7K | New |
| MILLENNIUM MANAGEMENT LLC | $9.3M | 807.8K | +18.5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.